{"url_path":"/sec/fth/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits, Financial Statement Schedules.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225333-index.html","accession_number":"0001193125-26-225333","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225333-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":554,"has_tables":true,"body_markdown":"Item 6. Exhibits, Financial Statement Schedules.\n\n(3) Exhibits\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39980), filed with the SEC on February 11, 2021).](https://www.sec.gov/Archives/edgar/data/1829802/000119312521037280/d95909dex31.htm)\n\n3.2\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39980), filed with the SEC on June 13, 2025).](https://www.sec.gov/Archives/edgar/data/1829802/000119312525140329/d945713dex31.htm)\n\n3.3\n\n \n\n[Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39980), filed with the SEC on December 9, 2022).](https://www.sec.gov/Archives/edgar/data/1829802/000119312522301836/d514100dex31.htm)\n\n3.4\n\n \n\n[Certificate of Designations of the Series A Junior Participating Cumulative Preferred Stock of the Registrant, dated March 7, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on March 7, 2023, File No. 005-92222)](https://www.sec.gov/Archives/edgar/data/1829802/000119312523063093/d470819dex31.htm)\n\n3.5\n\n \n\n[Certificate of Elimination of the Series A Junior Participating Cumulative Preferred Stock of the Registrant (incorporated by reference to Exhibit 3.4 to the Registrant’s Annual Report on Form 10-K (File No. 001-39980), filed with the SEC on March 28, 2025).](https://www.sec.gov/Archives/edgar/data/1829802/000095017025046338/snse-ex3_4.htm)\n\n3.6\n\n \n\n[Certificate of Designation of Series B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39980), filed with the SEC on February 18, 2026).](https://www.sec.gov/Archives/edgar/data/1829802/000119312526056135/d112826dex31.htm)\n\n10.1*#\n\n \n\n[Sensei Biotherapeutics, Inc. Severance and Change in Control Plan.](snse-ex10_1.htm)\n\n10.2*#\n\n \n\n[Sensei Biotherapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy.](snse-ex10_2.htm)\n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](snse-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](snse-ex31_2.htm)\n\n32.1**\n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](snse-ex32_1.htm).\n\n101.INS\n\n \n\nXBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents.\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n** This certification is being furnished solely to accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n79\n\n \n\n# Indicates management contract or compensatory plan.\n\n \n\n80\n\n \n\nSIGNATURES\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\nSensei Biotherapeutics, Inc.\n\nDate:\n\nMay 15, 2026\n\nBy:\n\n/s/ Christopher W. Gerry\n\nChristopher W. Gerry\n\nPresident and General Counsel\n\n \n\n \n\n \n\nPrincipal Executive Officer\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 15, 2026\n\nBy:\n\n/s/ Josiah Craver\n\n \n\n \n\n \n\n Josiah Craver\n\n \n\n \n\n \n\nSenior Vice President of Finance\n\n \n\n \n\n \n\nPrincipal Financial and Accounting Officer\n\n \n\n81"}